Executives of JD Health celebrate during a ceremony to mark the listing of the company on the Hong Kong Stock Exchange at JD headquarters in Beijing, Dec 8, 2020. (Photo: IC)

Genetron Holdings Ltd, a precision oncology platform company in China also known as Genetron Health, announced on Thursday a strategic partnership with JD Health, a subsidiary of Chinese e-commerce giant JD, to create innovative solutions for full-cycle cancer management.

The partnership encompasses both online and offline components, and focuses on six key areas, which are consumer healthcare, digitization of liver disease management, government medical associations, sharing of customer screening resources, industry and user education, and consolidation of oncology doctors and experts on a single platform.

The first phase of the partnership will focus on liver and lung cancer, Genetron Health said in a press release.

Genetron Health will cooperate with JD Health to cover early cancer screening, molecular profiling, therapy selection and drug resistance monitoring.

In May and June, the two companies will launch a series of marketing and educational activities for people at high risk of developing liver cancer. Meanwhile, JD Health’s online network of doctors and retail pharmacies will have an option to use Genetron Health’s products to help non-small cell lung cancer patients make their therapy selection decisions.

Xin Lijun, senior vice-president of JD and CEO of JD Health, said the two companies will explore the early liver cancer screening field together to enable earlier patient treatment and improve the penetration of liver cancer screening services in the industry.

Wang Sizhen, co-founder and CEO of Genetron Health, said the partnership combines his company’s precision oncology capabilities with JD Health’s leading online healthcare platform in China, representing an innovative commercialization strategy for molecular diagnostics products in oncology.